Serum fibulin‐1 levels and target organ damage in patients at high cardiovascular risk: A prospective observational study
European Journal of Clinical Investigation · 2025
DOI: 10.1111/eci.70039 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Journal of Clinical Investigation, 2025. Verfasst von Hack-Lyoung Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul Nation…. Hauptthemen laut MEDLINE: Calcium-Binding Proteins, Cardiovascular Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Seoul Metropolitan Government Seoul National University Boramae Medical Center.
Abstract (Originalsprache)
Background
Fibulin‐1, an extracellular matrix protein, is a potential biomarker for cardiovascular disease, but its association with target organ damage (TOD) in high‐risk patients remains unclear.
Methods
We prospectively analysed 330 patients undergoing invasive coronary angiography (ICA) (mean age, 64.7 ± 10.7 years; female, 37.9%). Blood samples obtained just before invasive coronary angiography (ICA) were stored for subsequent measurement of fibulin‐1 levels using an enzyme‐linked immunosorbent assay. During index admission, eight TOD parameters (obstructive coronary artery disease, impaired kidney function, increased arterial stiffness, left ventricular hypertrophy, left ventricular diastolic dysfunction and arterial occlusive disease of peripheral arteries) were assessed. Long‐term clinical follow‐up data on major adverse cardiovascular events (MACE) were also collected.
Results
Fibulin‐1 levels were significantly higher in patients with multiple TOD compared to those without (506 ± 229 vs. 354 ± 148 mcg/mL; p < .001). Serum fibulin‐1 levels increased proportionally with the number of TODs ( p < .001). Multivariable analyses identified that each 100 mcg/mL increase in serum fibulin‐1 level was significantly associated with an increased risk of multiple TOD, even after adjustment for potential confounders (odds ratio: 1.29–1.45; p < .05). Similarly, each 100 mcg/mL increase in serum fibulin‐1 level was associated with a 29% higher incidence of MACE (95% confidence interval, 1.14–1.46; p < .001).
Conclusions
Fibulin‐1 is strongly associated with the extent of TOD and may serve as a useful biomarker for risk stratification in high‐risk patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, South Korea.
- Division of Nephrology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, South Korea.
ORCID-Profile: Hack-Lyoung Kim
Förderung
- Seoul Metropolitan Government Seoul National University Boramae Medical Center
Zitieren
APA
Kim, H. L., Lee, J. P., & Lee, J. (2025). Serum fibulin‐1 levels and target organ damage in patients at high cardiovascular risk: A prospective observational study. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.70039
Vancouver
Kim HL, Lee JP, Lee J. Serum fibulin‐1 levels and target organ damage in patients at high cardiovascular risk: A prospective observational study. European Journal of Clinical Investigation. 2025. doi:10.1111/eci.70039
BibTeX
@article{Kim2025,
author = {Kim, Hack-Lyoung and Lee, Jung Pyo and Lee, Jeonghwan},
title = {Serum fibulin‐1 levels and target organ damage in patients at high cardiovascular risk: A prospective observational study},
journal = {European Journal of Clinical Investigation},
year = {2025},
doi = {10.1111/eci.70039}
}
EUVIMED